

Fabio Maino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4510434/publications.pdf>

Version: 2024-02-01

27
papers

726
citations

840776

11
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

1073
citing authors

#	ARTICLE	IF	CITATIONS
1	Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 of Endocrinology, 2011, 165, 441-446.	3.7	243
2	DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1623-1630.	3.6	109
3	Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. European Journal of Endocrinology, 2013, 169, 23-29.	3.7	80
4	Reference Range of Serum Calcitonin in Pediatric Population. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1780-1784.	3.6	40
5	Nodules in Autoimmune Thyroiditis Are Associated With Increased Risk of Thyroid Cancer in Surgical Series But Not in Cytological Series: Evidence for Selection Bias. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3193-3198.	3.6	35
6	Clinical presentation and management of patients with primary hyperparathyroidism in Italy. Journal of Endocrinological Investigation, 2018, 41, 1339-1348.	3.3	32
7	Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules. European Thyroid Journal, 2016, 5, 125-131.	2.4	25
8	Nodular Thyroid Disease in the Era of Precision Medicine. Frontiers in Endocrinology, 2019, 10, 907.	3.5	25
9	Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. Journal of Endocrinological Investigation, 2018, 41, 1029-1035.	3.3	24
10	Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2362-2368.	3.6	19
11	Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma?. Journal of Endocrinological Investigation, 2019, 42, 1205-1213.	3.3	12
12	Clinical significance of type 2 iodothyronine deiodinase polymorphism. Expert Review of Endocrinology and Metabolism, 2018, 13, 273-277.	2.4	11
13	Validation of American Thyroid Association Ultrasound Risk-Adapted Approach for Repeating Cytology in Benign Thyroid Nodules. Thyroid, 2021, 31, 446-451.	4.5	11
14	Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma. European Thyroid Journal, 2020, 9, 213-220.	2.4	8
15	Prognostic indicators for papillary thyroid carcinoma. Expert Review of Endocrinology and Metabolism, 2017, 12, 101-108.	2.4	7
16	Variants in MCT10 protein do not affect FT3 levels in athyreotic patients. Endocrine, 2019, 66, 551-556.	2.3	7
17	Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective caseâ€“control study in an Italian cohort. Journal of Endocrinological Investigation, 2019, 42, 693-698.	3.3	6
18	Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma. European Thyroid Journal, 2021, 10, 295-305.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Role of Age at Diagnosis in Defining Potential Familial Nonmedullary Thyroid Cancer in Kindreds With Two Affected Members. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e855-e865.	3.6	5
20	The Combination of Sonographic Features and the Seven-Gene Panel May be Useful in the Management of Thyroid Nodules With Indeterminate Cytology. <i>Frontiers in Endocrinology</i> , 2021, 12, 613727.	3.5	5
21	No need of glucocorticoid dose adjustment in patients with adrenal insufficiency before COVID-19 vaccine. <i>European Journal of Endocrinology</i> , 2022, 187, K7-K11.	3.7	5
22	Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 384.	2.4	4
23	Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients. <i>Frontiers in Endocrinology</i> , 2022, 13, 845954.	3.5	3
24	Clinical features of pediatric familial non-medullary thyroid cancer (FNMTC). <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2319-2321.	3.3	2
25	EIF1AX c.338-2A>T splice site mutation in a patient with trabecular adenoma and cytological indeterminate lesion. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 185-189.	0.6	2
26	Alteration of Serum Proteome in Levo-Thyroxine-Euthyroid Thyroidectomized Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1676.	2.4	1
27	Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 139-144.	3.3	0